The purpose of the present study was to develop immunotoxins directed against human ovarian carcinoma cells. Four monoclonal antibodies (260F9, 454(11, 2801)11, and 245E7) were chosen because they were found to bind to various ovarian carcinoma cell lines. These antibodies were covalently linked to either Pseudomonas exotoxin (PE) or ricin A chain (RTA), and the conjugates were tested against five ovarian cancer cell lines (OVCAR-2, -3, 4, -5; A1847). The ability of the immunotoxins to inhibit both protein synthesis and colony formation was tevaluated. Qualitatively similar results were obtained for both types of assays. Usually, PE conjugates were more toxic than their corresponding RTA conjugates. 454011-PE was very toxic for all ovarian carcinoma lines, whereas 454C11-RTA had low activity. Both 260F9-PE and 260F9-RTA were active in all OV-CAR cell lines but not in A1847 cells. 280D11-PE was toxic for OVCAR4; otherwise, 280D)1 -PE and RTA conjugates of both 280D11 and 245E7 had little activity. Specificity of immuiniotoxin action was shown by competition by excess antibody, nontoxicity in nontarget cells, and inactivity of an irrelevant immunotoxin.
Introduction
The availability of monoclonal antibodies (1) has opened new possibilities for cancer therapy because they can be used for targeting drugs (2) or toxins (3, 4) to cancer cells. We have begun to study the effects of antibody-toxin conjugates on human ovarian carcinoma cell lines in order to explore their potential usefulness as an alternative therapeutic approach to human ovarian cancer. Ovarian cancer is difficult to treat because these tumor cells often develop resistance to a broad spectrum of cytotoxic drugs (5) . These cells should be sensitive to antibodytoxin conjugates because the mechanism by which toxins kill cells is different from the mechanism of action of conventional chemotherapeutic agents. Because ovarian cancer remains localized in the peritoneal cavity even late in the course of the disease, immunotoxins could be administered intraperitoneally and, due to lymphatic obstruction (6) , would only be cleared slowly from the peritoneal cavity. Thus, high local concentrations of the agent could be achieved and maintained, and systemic toxicity could be limited.
We recently described the effect ofan antitransferrin receptor (anti-TFR)1-Pseudomonas exotoxin (PE) conjugate on five human ovarian carcinoma cell lines (7) . Although this immunotoxin inhibited protein synthesis in all cell lines tested, there were quantitative differences in the response ofvarious cell lines which were explained by differences in the binding and internalization of the immunotoxin and by different sensitivities to the toxin. Currently, it is not known whether the expression of transferrin receptors on normal tissues (8) would exclude the clinical use of an antitransferrin receptor conjugate. Therefore, we are also investigating the activity of other immunotoxins. The monoclonal antibodies used in this study were originally obtained against human breast cancer cells (9) and, when conjugated to ricin A chain (RTA), gave immunotoxins active against human breast cancer cell lines (10) . Because these antibodies were found to cross-react with some other carcinomas, and in particular with ovarian carcinomas (9), we used them to construct immunotoxins directed against human ovarian carcinoma cells by linking these antibodies to either PE or RTA.
Both PE and RTA must be delivered to the cytoplasm, where they inhibit protein synthesis either by inactivating elongation factor 2 through ADP-ribosylation, as in the case of PE ( 11) , or by blocking the ribosomal binding site for elongation factor 2, as in the case of RTA (12) . In the present paper, we describe the cytotoxic effects of these antibody-toxin conjugates on human ovarian carcinoma cell lines.
Methods
Cell culture. National Institutes of Health/OVCAR-2, -3, -4, and -5 are isolates from the malignant ascites of patients with ovarian carcinoma (13, 14) . The Antibodies. Monoclonal antibodies were obtained as described (9) . In addition to binding to human breast cancer cells, some ofthe antibodies were also found to bind to other carcinomas (9) . Four ofthese antibodies (260F9, 454Cl 1, 280Dl 1, and 245E7) were chosen for the present study because they were found to react with ovarian carcinoma cell lines as assessed by indirect immunofluorescence. The antibody 454Cl 1 is of the IgG-2a subclass, and the others are of the IgG-I subclass. Anti-TFR was purified from the ascites of nude mice bearing HB21 (American Type Culture Collection, Rockville, MD) as previously described (7).
Antibody-toxin conjugates. PE was a gift of Dr. S. Leppla (Ft. Detrick, Frederick, MD). PE conjugates were constructed and purified by a modification of a method previously described (7) . PE (30 nmol) was reacted with 5,000 nmol 2-iminothiolane-HCI (Pierce Chemical Co., Rockford, IL) and 500 nmol NAD+ in 1 ml 0.1 M phosphate buffer (pH 8.0) containing 1 mM EGTA at 37°C for 1 h. The derivatized PE was then separated from the reactants using high performance liquid chromatography (HPLC) and activated by the addition of 5,5'-dithio-bis(2-nitrobenzoic acid) (DTNB) to a final concentration of 1 mM. Antibodies (40-50 nmol) were incubated with 100-200 nmol 2-iminothiolane-HCl in 0.75 ml 0.1 M phosphate buffer (pH 8.0) containing 1 mM EGTA at 37°C for 1 h. Then antibodies were reacted with the activated PE, and the conjugates were purified using HPLC as described (7) . A peak containing a one-to-one conjugate of PE with the antibody was recovered and used for all studies described below. RTA conjugates were prepared by incubating RTA with antibody which had been activated by incubation with 2-iminothiolane and DTNB. They were purified by gel filtration chromatography to remove unreacted RTA and affinity chromatography to remove unreacted antibody. A detailed description of this procedure and the resulting product will be published (Bloch, W., R. Ferris, D. Birch, and J. Ellingson, manuscript in preparation).
Protein synthesis assay. Inhibition of protein synthesis was used to measure the activity of the immunotoxins. Cells were incubated with DME-BSA containing various concentrations of immunotoxins at 37°C for 24 h and then assayed for incorporation of [3H]leucine (New England Nuclear, Boston, MA; specific activity, 140.8 Ci/mmol) into TCA-insoluble material as described previously (7) . Mean values of duplicates were expressed as a percentage of controls that did not receive immunotoxins.
Colony formation assay. About 500 cells were plated in a 60-mm dish containing 5 ml medium and various concentrations of immunotoxins. The cells were incubated at 37°C for 8-14 d. Then, the medium was removed and the colonies were stained with 0.5% methylene blue in ethanol/water (1:1). After washing and drying, the colonies were counted and the results were expressed as a percentage of the controls that were incubated without immunotoxin.
Binding Table I . Fig. 2 shows experiments in which OVCAR-2 cells were incubated with various immunotoxins. 454C1 1-PE, 260F9-PE, and 260F9-RTA were very active, with ID50 values (Table I) of 2 ng/ml for 454C1 1-PE, 3 ng/ml for 260F9-PE, and 38 ng/ml for 260F9-RTA. The unconjugated antibody competed for the toxicity of the corresponding immunotoxin. 280D1 1-PE inhibited protein synthesis only at concentrations >100 ng/ml. RTA conjugates ofeither 454C1 1, 280D1 1, or 245E7 showed little activity ( Fig. 2 and Table I ).
For OVCAR-3 cells (Fig. 3 ), 454C1 1-PE was very active; only at very high immunotoxin concentrations, and were >100-fold less active than 260F9 conjugates or 454CI 1-PE.
Average ID50 values of all of the colony formation experiments are summarized in Table II. In the OVCAR cell lines tested, 454C 1 -PE and conjugates of 260F9 had the highest activity. Also, in this assay, 260F9-PE was more active than 260F9- RTA (except in OVCAR-3). In A 1847 cells, 454C1 1-PE at 0.4 ng/ml led to 50% inhibition of colony formation, whereas the ID50 values for the other immunotoxins were > 10 ng/ml. Internalization ofmonoclonal antibodies. In OVCAR-2 cells, 454C 1 I-PE was the most active immunotoxin, followed by 260F9-PE and 260F9-RTA, whereas 454C 1 I-RTA and both conjugates of280D 11 showed little or no activity. To investigate possible reasons for these different activities, we studied the internalization of the following antibodies in OVCAR-2 cells: 260F9, 280Dl 1, 454Cl 1, and anti-TFR. When studied by indirect immunofluorescence, all these antibodies bound to the cell surface, and there were often quantitative differences in reactivity among cells from a single cell line. Only anti-TFR reacted in a uniform manner with all cells from the same cell line. As shown in Fig. 1 , anti-TFR was efficiently internalized, and after a 1-h incubation at 37°C a punctate and presumably lysosomal distribution of the antibody was observed (15) . Both 260F9 and 454C 1 I showed a much brighter surface pattern than anti-TFR at time zero (no warmup). After 1 h at 37°C, definite uptake of antibody into vesicles, although less than that observed with anti-TFR, was seen. No internalization of 280Dl 1 antibodies could be detected under the same conditions.
Discussion
We have identified three immunotoxins that were very active against human ovarian carcinoma cell lines: 454C 11 -PE was toxic for all five ovarian cell lines studied, whereas 260F9-PE and 260F9-RTA were active in all OVCAR cell lines but not in A 1847 cells. In contrast to these potent immunotoxins, 454C I I -RTA as well as immunotoxins constructed from either 280D 11 or 245E7 showed little or no activity towards the ovarian carcinoma cell lines except 280Dl l-PE in OVCAR-4 (Tables I and  II) . In a given cell type, the toxicity of the various antibodytoxin conjugates was dependent on both the antibody and the toxin components. Specificity of our active immunotoxins was shown in several ways: (a) Excess antibody competed for the toxicity of the corresponding immunotoxin, indicating that the conjugates bound to the cell surface via the antibody. (b) The immunotoxins had low activity on nontarget cells. In the colony formation assay, OVCAR cells were 260-fold to 20,000-fold more sensitive to 260F9-PE or 260F9-RTA than nontarget KB cells (Table II) . In addition to our results with KB cells, RTA conjugates of the antibodies used in this study were found to be inactive in two human fibroblast cell lines (10) . (c) An irrelevant immunotoxin, such as PE linked to an antibody against the human T cell growth factor receptor (16) , has previously been shown to be inactive in the OVCAR cells (7) .
Although qualitatively similar results were obtained for both types of assays, ID50 values were up to 250-fold lower in the colony formation assay. One explanation for this finding is that cells exposed longer die because the toxin is catalytic, and even a single molecule in the cytoplasm will eventually kill the cell (17) . Because very high concentrations of immunotoxins showed nonspecific inhibition of protein synthesis in KB cells, the difference in ID50 values between target ovarian cells and nontarget KB cells was less in the protein synthesis inhibition assay than in the colony formation assay where lower immunotoxin concentrations were used.
To be cytotoxic, PE or RTA must be delivered to the cytoplasm, where it can inactivate protein synthesis. In a given cell line, therefore, antibody-dependent differences in toxicity ofimmunotoxins containing one particular toxin could be due to the differences in rate and extent of antibody internalization. To investigate this, we looked at the cellular uptake ofthe antibodies by OVCAR-2 cells. Under the conditions used, anti-TFR, 260F9, and 454Cl 1 were internalized, but 280Dl 1 could not be detected intracellularly. These results could explain why in OVCAR-2 cells PE conjugates of anti-TFR (7), 260F9, or 454Cl 1 were much more toxic than those of 280D 1. However, despite internalization of 454Cl 1, the RTA conjugate of this antibody had low activity, suggesting that additional factors influence the activity of immunotoxins. Nevertheless, poor internalization of an antibody indicates that immunotoxins constructed with this antibody will have low activity.
For a given antibody, PE conjugates were usually more active than their RTA counterparts. These differences may be due to the fact that PE conjugates contain the entire toxin molecule, whereas RTA conjugates lack the B subunit that facilitates membrane permeation (18) . However, we cannot exclude the possibility that subtle differences in the disulfide linkage favored the retention of a higher binding affinity by the antibodies when linked to PE.
This study suggests that 454Cl l-PE, 260F9-PE, and 260F9-RTA are potential candidates for therapy of human ovarian carcinoma. Ongoing in vivo studies using a xenograft model of human ovarian carcinoma in nude mice (19) should answer whether sufficient in vivo targeting can be achieved and, additionally, will provide more data on the pharmacokinetics and side effects ofthese immunotoxins. Finally, it remains to be seen whether the activity of these immunotoxins, in particular of the ones with low activity, could specifically be increased by one of the methods reported to enhance the toxicity of immunotoxins (18, (20) (21) (22) (23) (24) (25) .
